| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Tracey Brown | |
| Jonathan Berman | |||
| Stephen Toovey | |||
| Geoffrey Dow | |||
| P2860 | cites work | A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria | Q28204425 |
| Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia | Q31030931 | ||
| Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects | Q33613720 | ||
| Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. | Q33806574 | ||
| Toxicity of primaquine in Caucasians | Q33975955 | ||
| Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. | Q33999450 | ||
| Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. | Q34288516 | ||
| Mefloquine induces dose-related neurological effects in a rat model | Q34509705 | ||
| The nature of relapse in schizophrenia | Q34581127 | ||
| Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) | Q35181605 | ||
| THE TOXICITY OF LARGE DOSES OF PENTAQUINE (SN-13,276), A NEW ANTIMALARIAL DRUG. | Q35306681 | ||
| PENTAQUINE (SN-13,276), A THERAPEUTIC AGENT EFFECTIVE IN REDUCING THE RELAPSE RATE IN VIV AX MALARIA. | Q35306715 | ||
| Methamphetamine psychosis: epidemiology and management | Q37265315 | ||
| Mefloquine neurotoxicity: a literature review | Q37378828 | ||
| Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis | Q38376925 | ||
| Tafenoquine is not neurotoxic following supertherapeutic dosing in rats | Q38684922 | ||
| Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine | Q39199497 | ||
| Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys | Q42115534 | ||
| The New Synthetic Drugs | Q42347593 | ||
| Plasmodium cynomolgi infections in the rhesus monkey | Q44167110 | ||
| The impact of Malarone and primaquine on psychomotor performance | Q44513850 | ||
| Mefloquine for preventing malaria during travel to endemic areas | Q47140318 | ||
| First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. | Q47831031 | ||
| Low dosage promethazine and loratadine negatively affect neuromotor function | Q48285616 | ||
| Plasmocid encephalopathy in the rhesus monkey: a study of selective vulnerability | Q48649462 | ||
| Recurrence in affective disorder. I. Case register study. | Q50897602 | ||
| Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report | Q56525975 | ||
| Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey | Q75803343 | ||
| Neurotoxicity of the 8-aminoquinolines; lesions in the central nervous system of the rhesus monkey induced by administration of plasmocid | Q79498993 | ||
| Pamaquine poisoning in man, with a clinicopathologic study of one case | Q80378702 | ||
| Neurotoxicity of the 8-aminoquinolines; reactions of various experimental animals to plasmocid | Q80644165 | ||
| Plasmochin toxicity; analysis of 258 cases | Q82143420 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| P304 | page(s) | 407 | |
| P577 | publication date | 2018-11-06 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines | |
| P478 | volume | 17 |
Search more.